Considering the global impact of HIF on cancer cells and the TME, therapies targeting HIF activity, such as the usage of small molecules preventing the interactions of the HIF-α and HIF1-β subunits214, can be beneficial for some groups of patients. The gene discussed is HIF1A; the disease is cancer.